Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. (2016)
Attributed to:
Gene-expression connectivity mapping and its application in phenotypic targeting
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.18632/oncotarget.6773
PubMed Identifier: 26735888
Publication URI: http://europepmc.org/abstract/MED/26735888
Type: Journal Article/Review
Volume: 7
Parent Publication: Oncotarget
Issue: 6
ISSN: 1949-2553